Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
about
Applications of 211At and 223Ra in targeted alpha-particle radiotherapyCombination Radioimmunotherapy Approaches and Quantification of Immuno-PETDosimetry for radiopharmaceutical therapyAn overview of targeted alpha therapy.Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapyRadioimmunotherapy with α-particle-emitting radionuclides.Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.Cancer radioimmunotherapy.DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.Molecular targeted α-particle therapy for oncologic applications.A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.Emerging trends for radioimmunotherapy in solid tumorsSelf-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery.Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.Radioimmunotherapy of solid tumors: searching for the right target.Modelling and dosimetry for alpha-particle therapy.Actinium-225 in targeted alpha-particle therapeutic applications.Where does radioimmunotherapy fit in the management of breast cancer?Matching chelators to radiometals for radiopharmaceuticals.Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer modelα- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry.Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer.Present and Future Prospects of Radiation Therapy Using α-Emitting Nuclides.212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.Drug conjugates—an emerging approach to treat breast cancer.α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10.Structure and properties of DOTA-chelated radiopharmaceuticals within the Ac decay pathway
P2860
Q24610016-0F077F2B-E2EE-4A7A-93B7-89C6AC7F4558Q26747546-216EDD20-CAB1-430A-BF18-30B75B21E8D6Q33665116-311F9009-A404-4133-9638-55FEEDAADC76Q34238513-0BA0C903-2564-4146-85D0-8337CF28FC33Q34296503-FF9B9865-1BD9-44F7-BD4A-B876814F5F58Q34324413-9A2A6A1F-3AC5-4E69-876B-FE913BF4A9A2Q34419562-815367C5-6891-4C76-9F86-DC1E7AFE06A7Q34555716-F8EE9DD8-2E0E-42CA-A23C-89F7A2FF7B5DQ35070045-D3598C1F-541C-4119-918D-F0CCAD5433C0Q35091643-F23FBC4F-5E4F-4CA8-A1EE-7C200ECF708CQ35814989-F12D19F9-3D3C-47A3-BAAA-F5AB26C59BD2Q35818377-BF50B22F-8C14-4573-9B4D-D2F2B00323C3Q36723768-65FF40AA-9C6C-4EF7-8BF7-B40E271066DCQ36777329-5AC9E9DE-E28A-43FC-A98E-20801BF9EE81Q37222795-C3AE8895-C153-4C49-A6C4-B9490AF56C00Q37233043-086846C2-36C1-486C-9894-6D651A040942Q37244880-CD6A011E-5368-4BE6-A4A1-B32420B66439Q37362912-9E7C9A05-D537-43C1-9BB0-928CAE2A7B32Q37804904-D791857A-2A9D-47A5-9A7F-54107770B879Q37971507-075373E8-8EDA-4917-97EA-02F066A2559EQ37971807-6ED0FB2A-4A2B-4A4C-B363-2795C9EAD61CQ38125535-967883B9-18C2-4F6F-9601-2936D45127EEQ38156660-8FC97051-110A-40FB-9E1D-F50E783A09B7Q38672855-4EAA40C8-086A-461E-87C4-60A36639D749Q38715106-64C7B2A7-DB6C-4FC4-96DC-1DE1D4B9D7EEQ38724752-5B65A34E-7D1C-4CB2-B0F8-42FEDB5FFCD3Q39413582-BF5F17FD-4730-493E-A086-65007070C483Q40254341-1406D37D-F2D1-46B8-BD95-CB47D7FE04F0Q41776636-06AD1A38-5626-443E-9C4F-4703ED5BC14CQ47703463-8711C3F9-B3BD-4D25-9489-7223267C1543Q55042518-4E009CF0-C847-47CD-BF8C-028E2F82582DQ55438401-79C03466-C4FB-47B5-9551-C88F4C7156B1Q55509262-80BBBBBD-F31E-4C3D-97E7-9B877DF9DB8DQ57179186-C7D78443-6B87-4E5A-A7AF-91FEE380FCBE
P2860
Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Radioimmunotherapy of breast c ...... g efficacy with 213Bi and 90Y.
@en
Radioimmunotherapy of breast c ...... g efficacy with 213Bi and 90Y.
@nl
type
label
Radioimmunotherapy of breast c ...... g efficacy with 213Bi and 90Y.
@en
Radioimmunotherapy of breast c ...... g efficacy with 213Bi and 90Y.
@nl
prefLabel
Radioimmunotherapy of breast c ...... g efficacy with 213Bi and 90Y.
@en
Radioimmunotherapy of breast c ...... g efficacy with 213Bi and 90Y.
@nl
P2093
P2860
P1433
P1476
Radioimmunotherapy of breast c ...... g efficacy with 213Bi and 90Y.
@en
P2093
Alfred Morgenstern
Caroline Esaias
Christos Apostolidis
David L Huso
Ravy Vajravelu
P2860
P304
P356
10.1158/0008-5472.CAN-09-1828
P407
P577
2009-11-17T00:00:00Z